Abstract | OBJECTIVE: ω-3 polyunsaturated fatty acids (PUFA) are a key modifiable factor in the intervention of type 2 diabetes, yet recommendations for dietary consumption of ω-3 PUFA in type 2 diabetes remain ambiguous and controversial. Here, we revisit the subject in the light of population pharmacokinetic-pharmacodynamic (PPK-PD) modeling and propose a threshold for intake. RESEARCH DESIGN AND METHODS: Plasma levels of ω-3 PUFA and glycosylated hemoglobin (HbA1c) were measured as pharmacokinetic and pharmacodynamic indicator, respectively. The nonlinear mixed effect analysis was used to construct a PPK-PD model for ω-3 PUFA and to quantify the effects of FADS gene polymorphism, age, liver and kidney function, and other covariables. RESULTS: Data from 161 patients with type 2 diabetes in the community were modeled in a two-compartment model with primary elimination, and HDL was a statistically significant covariate. The simulation results showed that HbA1c showed a dose-dependent decrease of ω-3 PUFA plasma level. A daily intake of ω-3 PUFA at 0.4 g was sufficient to achieve an HbA1c level of 7% in more than 95% of patients. CONCLUSIONS: PPK/PD modeling was proposed as a multilevel analytical framework to quantitatively investigate finer aspects of the complex relationship between ω-3 PUFA and type 2 diabetes on genetic and non-genetic influence factors. The results support a beneficial role for ω-3 PUFA in type 2 diabetes and suggested the intake threshold. This new approach may provide insights into the interaction of the two and an understanding of the context in which changes occur.
|
Authors | Ling Wang, Xiaomin Huang, Mingyao Sun, Tian Zheng, Luyan Zheng, Xiaolan Lin, Junshan Ruan, Fan Lin |
Journal | Nutrition & diabetes
(Nutr Diabetes)
Vol. 14
Issue 1
Pg. 8
(Mar 04 2024)
ISSN: 2044-4052 [Electronic] England |
PMID | 38438344
(Publication Type: Journal Article)
|
Copyright | © 2024. The Author(s). |
Chemical References |
- Fatty Acids, Omega-3
- Glycated Hemoglobin
|
Topics |
- Humans
- Diabetes Mellitus, Type 2
(drug therapy)
- Fatty Acids, Omega-3
- Glycated Hemoglobin
- Liver
|